Topic: Lung cancer.
Destination: LCRF has launched a new funding mechanism to support research projects with a focus on characterizing, identifying, treating or overcoming/preventing resistance to therapies in tumors harboring alterations in oncogenic drivers in NSCLC cells, tissues, mouse models, or patients. Work supported through this mechanism will addresses important mechanistic questions and developmental therapeutics across the care continuum and have the potential to increase survivorship. In 2022, in partnership with leading patient advocacy organizations, this grant mechanism will focus on three specific oncogenes: EGFR, MET and KRAS.
Budget: $150,000
Duration: 2 years.
Omple el següent formulari per rebre més informació:
Galeta | Durada | Descripció |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |